Folic acid and ferritin functionalized reduced Iron-based metal-organic frameworks for anticancer therapy

Abstract

Anticancer chemotherapies damage normal tissues and various drug carriers are under consideration to address this issue. Metal-organic frameworks (MOFs) are promising due to their drug-carrying capacity and tunable properties and target-inspired surface functionalization magnify their potential. In this study, we aim to investigate the anticancer activity of reduced iron-based MOFs (FeMOFs) functionalized with ferritin and folic acid and loaded with doxorubicin. Successful synthesis and functionalization are confirmed by Electron microscopes, Fourier transform infrared spectroscopy and X-ray diffraction. Anticancer activity is evaluated in different tumor cell lines at various doses. Results indicate that the folic acid functionalized MOF (FADMOF) showed maximum anticancer potential, leaving only 6 % of 4 T1 cells alive at the highest dose. While Ferritin and combo MOFs followed closely followed, and empty MOFs (RMOF) lagged. Further, in HeLa cells, the plain MOF (RMOF) shows best cytotoxicity reducing cell viability to a mere 30 % at the highest dose. Similarly, in MCF7 cells, the plain MOF (RMOF) shows best cytotoxicity reducing cell viability to a mere 25 % at the highest dose in a dose-dependent manner. Taken together, this study shows that functionalized MOFs have promising anticancer potential across various cancer cell lines. However, loading with Doxorubicin reduces their cytotoxicity.